Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC)

Hormone Receptor ◽

Metastatic Breast ◽

First Line ◽

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis

Breast Cancer ◽

10.1007/s12282-020-01054-7 ◽

2020 ◽

Vol 27 (3) ◽

pp. 340-346 ◽

Cited By ~ 1

Author(s):

Tatsunori Shimoi ◽

Yasuaki Sagara ◽

Fumikata Hara ◽

Tatsuya Toyama ◽

Hiroji Iwata

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Meta Analysis ◽

Metastatic Breast ◽

First Line ◽

Abstract PS12-21: First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry

10.1158/1538-7445.sabcs20-ps12-21 ◽

2021 ◽

Author(s):

Gabriel Rinnerthaler ◽

Simon P Gampenrieder ◽

Christoph Tinchon ◽

Andreas Leo Petzer ◽

Christoph Suppan ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Everyday Practice ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis

Current Problems in Cancer ◽

10.1016/j.currproblcancer.2020.100606 ◽

2020 ◽

Vol 44 (6) ◽

pp. 100606 ◽

Cited By ~ 1

Author(s):

Yiqun Han ◽

Jiayu Wang ◽

Zijing Wang ◽

Binghe Xu

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Hormone Receptor ◽

Meta Analysis ◽

Metastatic Breast ◽

Mtor Inhibitors ◽

Efficacy And Safety ◽

Comparative Efficacy ◽

The CAN BEAR study: A systematic review and meta-analysis investigating adverse events (AEs) of targeted agents added to endocrine therapy (ET) in patients (pts) with hormone-receptor positive (HR+) metastatic breast cancer (MBC)

Annals of Oncology ◽

10.1093/annonc/mdx365.052 ◽

2017 ◽

Vol 28 ◽

pp. v95-v96

Author(s):

S. Martel ◽

M. Bruzzone ◽

M. Ceppi ◽

C. Maurer ◽

N. Falbel Ponde ◽

...

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Adverse Events ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Meta Analysis ◽

Metastatic Breast ◽

Targeted Agents ◽

Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2- Positive Metastatic Breast Cancer (MBC) – Results of theeLEcTRATrial.

10.1158/0008-5472.sabcs-09-4094 ◽

2009 ◽

Cited By ~ 6

Author(s):

J. Huober ◽

P. Fasching ◽

S. Paepke ◽

E. Kubista ◽

M. Barsoum ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

First Line Treatment

Abstract P6-10-05: First-line chemotherapy versus first-line endocrine therapy in hormone receptor positive HER2 negative patients with metastatic breast cancer in China: Results of the study of breast cancer group of the Chinese Society of Clinical Oncology (CSCO)

10.1158/0008-5472.sabcs13-p6-10-05 ◽

2013 ◽

Author(s):

T Wang ◽

TT Yang ◽

LJ Yang ◽

HY Song ◽

CQ Ouyang ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Chinese Society ◽

First Line ◽

Cancer Group ◽

Breast Cancer Group ◽

Line Chemotherapy

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients

European Journal of Cancer ◽

10.1016/j.ejca.2018.03.013 ◽

2018 ◽

Vol 95 ◽

pp. 93-101 ◽

Cited By ~ 14

Author(s):

E. Jacquet ◽

A. Lardy-Cléaud ◽

B. Pistilli ◽

S. Franck ◽

P. Cottu ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Hormone Receptor ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

First Line Therapy ◽

Line Therapy

Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.531 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 531-531

Author(s):

Antoinette R. Tan ◽

Serena Tsan-Lai Wong ◽

Robert D. Warren ◽

Jennifer Eng-Wong ◽

Minetta C. Liu ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Hormone Receptor ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Line Therapy

First‐Line Treatment Patterns and Clinical Outcomes in Patients With HER2‐Positive and Hormone Receptor‐Positive Metastatic Breast Cancer From registHER

The Oncologist ◽

10.1634/theoncologist.2012-0414 ◽

2013 ◽

Vol 18 (5) ◽

pp. 501-510 ◽

Cited By ~ 37

Author(s):

Debu Tripathy ◽

Peter A. Kaufman ◽

Adam M. Brufsky ◽

Musa Mayer ◽

Marianne Ulcickas Yood ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Treatment Patterns ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

First Line Treatment